



Atty Dkt No. 029996-0278721
Pat. App. Ser. No. 09/804,409

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Kieffer et al.

Group Art Unit: 1632

Appln. No.: 09/804,409

Examiner: P. Para, Jr.

Filed: March 12, 2001

Title:
COMPOSITIONS AND METHODS FOR
REGULATED PROTEIN EXPRESSION IN
GUT

INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is Form PTO-1449 listing the enclosed cited references in this statement.

This IDS is being filed with a request for continued examination under Rule 114, and hence this IDS must be considered per Rule 97(b)(4).

Certificate of Mailing Under 37 C.F.R. §1.10

I hereby certify that this correspondence (along with any paper referred to as being attached or enclosed) is being mailed via "Express Mail Post Office to Addressee" service of the United States Postal Service (Express Mail Label No. EL 988001674 US) on the date shown below in an envelope addressed to the Commissioner of Patent & Trademarks, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

By: _____

Sachiko Y. Snedden

Date: _____

June 16, 2004

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

This Information Disclosure Statement is not to be constructed as a representation that any of the listed citations establishes, by itself or in combination with other information, a prima facie case of unpatentability of any claim in the above-identified patent application. Additionally, this Information Disclosure Statement is not to be constructed as a representation that a further search of the art has been made by the Applicant, or that additional information unknown to the Applicant and relevant to the examination of this patent application does not exist.


Consideration of the foregoing and enclosures plus the return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 are earnestly solicited along with an early action on the merits.

Respectfully submitted,

Pillsbury Winthrop LLP

Date: June 16, 2004

By


Robert M. Bedgood, Ph.D.
Reg. No. 43,488

Tel. No. (858) 509-4065

Fax No. (858) 509-4010

11682 El Camino Real
Suite 200
San Diego, CA 92130-2092
(619) 234-5000

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PW FORM PAT-1449)
 Patent and Trademark Office

Atty.
Dkt. No.

C-M#

Client Ref.

029996-0278721

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Kieffer, et al.

Appln. No.: 09/804,409

Filing Date: March 12, 2001

Date: June 16, 2004

Page

1

of

2

Examiner: P. Paras, Jr.

Art Unit: 1632

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR	5,821,235	10/1998	Henning et s-al.			
	BR	5,989,910	11/1999	Mermod et al.			
	CR	6,004,941	12/1999	Bujard et al.			
	DR	6,004,944	12/1999	Rothman et al.			
	ER	6,015,709	01/2000	Nitesan			
	FR	6,110,456	08/2000	During			
	GR	6,503,887	07/2003	During			

FOREIGN PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract		Translation Readily Available	
							Enclosed	No	Enclosed	No
	HR	00/57921	10/2000	WO	During					
	IR	2 364 417	10/2000	CA	During					

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

C-

Client Ref.

029996-0278721

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Kieffer, et al.

Appln. No.: 09/804,409

Filing Date: March 12, 2001

Date: June 16, 2004

Page

2

of

2

Examiner: P. Paras, Jr.

Art Unit: 1632

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner's

Initials*

English

Abstract

Translation

Readily
Available

Enclosed

No

Enclosed

No

JR

Lee et al.; Glucagon Gene 5'-Flanking Sequences Direct Expression of Simian Virus 40 large T Antigen to the Intestine, Producing Carcinoma of the Large Bowel in Transgenic Mice; J. Biol. Chem, vol. 267, no. 15; May 1992; pp. 10705-10708

KR

Gajic et al.; Multiple *cis*-Acting Domains Mediate Basal and Adenosine 3',5'-Monophosphate-Dependent Glucagon Gene Transcription in a Mouse Neuroendocrine Cell Line; Endocrinology, vol. 132, no. 3; 1993; pp. 1055-1062

LR

Henning; Gene transfer into the intestinal epithelium; Advanced Drug Review, vol. 17; 1995; pp. 341-347

MR

Kolodka et al.; Gene Therapy for Diabetes Mellitus in Rats by Hepatic Expression of Insulin; Proc. Natl. Acad. Sci. USA, vol. 92; April 1995; pp. 3293-3297

NR

Efrat et al.; Glucagon Gene Regulatory Region Directs Oncoprotein Expression to Neurons and Pancreatic α Cells; Neuron, vol. 1; September 1998; pp. 605-613

OR

Boylan et al.; Cell-specific Expression of the Glucose-dependent Insulinotropic Polypeptide Gene in a Mouse Neuroendocrine Tumor Cell Line; The Journal of Biological Chemistry, vol. 272, no. 28; July 1997; pp. 17438-17443

PR

Croyle et al.; In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine; Gene Therapy, vol. 5; 1998; pp. 645-654

QR

Yeung et al.; Glucose-dependent insulinotropic polypeptide gene expression in the stomach: revealed by a transgenic mouse study, in situ hybridization and immunohistochemical staining; Molecular and Cellular Endocrinology, vol. 154; 1999; pp. 161-170

RR

Rutter et al.; Regulation of Mammalian Gene Expression by Glucose; News Physiol. Sci., vol. 15; June 2000; pp. 149-154.

SR

During et al.; Peroral gene therapy of lactose intolerance using an andeno-associated virus vector; Nature Medicine, vol. 4, no. 10; October 1998; pp. 1131-1135

TR

During et al.; An Oral Vaccine Against NMDAR1 with Efficacy in Experimental Stroke and Epilepsy; Science; vol. 287; February 2000; pp. 1453-1460

UR

Morsy et al.; Leptin gene therapy and daily protein administration: a comparative study in the ob/ob mouse; Gene Therapy, vol. 5; 1998; pp. 8-18

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.